CL2017000494A1 - Tratamientos médicos a base de anamorelina. - Google Patents
Tratamientos médicos a base de anamorelina.Info
- Publication number
- CL2017000494A1 CL2017000494A1 CL2017000494A CL2017000494A CL2017000494A1 CL 2017000494 A1 CL2017000494 A1 CL 2017000494A1 CL 2017000494 A CL2017000494 A CL 2017000494A CL 2017000494 A CL2017000494 A CL 2017000494A CL 2017000494 A1 CL2017000494 A1 CL 2017000494A1
- Authority
- CL
- Chile
- Prior art keywords
- anamorelin
- anamoreline
- cancer
- medical treatments
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
<p>SE DESCRIBEN MÉTODOS DE TRATAMIENTO DE AFECCIONES RELACIONADAS CON EL CÁNCER USANDO ANAMORELINA. LA MODALIDAD PRINCIPAL SE RELACIONA CON LA AFECCIÓN ÚNICA DE PACIENTES QUE LA DEFINEN MEDIANTE EL TRATAMIENTO DE LA CAQUEXIA EN UN PACIENTE HUMANO CON CÁNCER, QUE COMPRENDE LA ADMINISTRACIÓN A DICHO PACIENTE DE UNA CANTIDAD TERAPÉUTICAMENTE EFECTIVA DE ANAMORELINA DURANTE UN PERÍODO TERAPÉUTICAMENTE EFECTIVO, Y LA SORPRENDENTE CAPACIDAD OBSERVADA DE LA ANAMORELINA DE AUMENTAR LA MASA CORPORAL MAGRA DE ESTA POBLACIÓN.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045976P | 2014-09-04 | 2014-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000494A1 true CL2017000494A1 (es) | 2017-09-15 |
Family
ID=55436476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000494A CL2017000494A1 (es) | 2014-09-04 | 2017-03-02 | Tratamientos médicos a base de anamorelina. |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| GEP20186939B (en) | 2014-09-04 | 2018-12-25 | Healthcare Sa Helsinn | Medical treatments based on anamorelin |
| WO2020037151A1 (en) | 2018-08-16 | 2020-02-20 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy with maintenance dose |
| CA3123605A1 (en) | 2018-12-20 | 2020-06-25 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy dosing schedule for missed doses |
| EP3965815A4 (en) | 2019-05-10 | 2023-05-31 | Société des Produits Nestlé S.A. | METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT |
| BR112022002767A2 (pt) | 2019-08-30 | 2022-05-10 | Helsinn Healthcare Sa | Métodos de fabricação de um comprimido de cloridrato de anamorelina, comprimidos e método para melhorar um ou mais sintomas de caquexia de câncer |
| BR112022005457A2 (pt) * | 2019-10-24 | 2022-06-21 | Toray Industries | Agente terapêutico ou profilático para caquexia |
| JP2024534464A (ja) * | 2021-09-17 | 2024-09-20 | 小野薬品工業株式会社 | 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法 |
| JPWO2025004650A1 (es) * | 2023-06-28 | 2025-01-02 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| ECSP993020A (es) | 1999-06-16 | 1999-08-12 | Terapia de combinacion para la fragilidad musculoesqueletica | |
| ECSP993021A (es) | 1999-06-16 | 1999-08-12 | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
| US20010020012A1 (en) | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
| CN1863550A (zh) * | 2003-08-06 | 2006-11-15 | 加斯特罗泰克药物公司 | 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用 |
| WO2005014032A2 (en) * | 2003-08-06 | 2005-02-17 | Gastrotech Pharma A/S | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
| KR20070010151A (ko) | 2004-03-30 | 2007-01-22 | 사파이어 세라퓨틱스, 인크. | 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법 |
| CN1976921B (zh) * | 2004-06-29 | 2013-08-21 | 蓝宝石治疗公司 | (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形 |
| WO2008100448A2 (en) * | 2007-02-13 | 2008-08-21 | Helsinn Therapeutics (U.S.), Inc. | Method of treating cell proliferative disorders using growth hormone secretagogues |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| JO3353B1 (ar) * | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| WO2013175805A1 (en) * | 2012-05-25 | 2013-11-28 | Raqualia Pharma Inc. | Ghrelin receptor agonists for the treatment of achlorhydria |
| GEP20186939B (en) | 2014-09-04 | 2018-12-25 | Healthcare Sa Helsinn | Medical treatments based on anamorelin |
-
2015
- 2015-08-28 GE GEAP201514459A patent/GEP20186939B/en unknown
- 2015-08-28 ME MEP-2019-372A patent/ME03597B/me unknown
- 2015-08-28 SG SG11201701567UA patent/SG11201701567UA/en unknown
- 2015-08-28 RS RS20191688A patent/RS59751B1/sr unknown
- 2015-08-28 EA EA201790352A patent/EA035578B1/ru unknown
- 2015-08-28 KR KR1020217008765A patent/KR102307275B1/ko active Active
- 2015-08-28 MA MA40607A patent/MA40607B1/fr unknown
- 2015-08-28 MY MYPI2017700714A patent/MY187167A/en unknown
- 2015-08-28 SI SI201530994T patent/SI3188599T1/sl unknown
- 2015-08-28 GE GEAP201814459A patent/GEAP201814459A/en unknown
- 2015-08-28 JP JP2017512679A patent/JP6356907B2/ja active Active
- 2015-08-28 AU AU2015312231A patent/AU2015312231B2/en active Active
- 2015-08-28 UA UAA201702308A patent/UA120765C2/uk unknown
- 2015-08-28 PE PE2017000359A patent/PE20171109A1/es unknown
- 2015-08-28 CA CA2959158A patent/CA2959158A1/en active Pending
- 2015-08-28 TN TN2017000040A patent/TN2017000040A1/en unknown
- 2015-08-28 ES ES15838548T patent/ES2761777T3/es active Active
- 2015-08-28 CN CN201580059744.3A patent/CN107205389A/zh active Pending
- 2015-08-28 EP EP19183144.5A patent/EP3590338A3/en not_active Withdrawn
- 2015-08-28 CN CN202111026050.3A patent/CN113577073A/zh active Pending
- 2015-08-28 CR CR20170121A patent/CR20170121A/es unknown
- 2015-08-28 CN CN202111027023.8A patent/CN113577074A/zh active Pending
- 2015-08-28 DK DK15838548T patent/DK3188599T3/da active
- 2015-08-28 KR KR1020177008748A patent/KR101881264B1/ko active Active
- 2015-08-28 HR HRP20192345TT patent/HRP20192345T1/hr unknown
- 2015-08-28 HU HUE15838548A patent/HUE046894T2/hu unknown
- 2015-08-28 US US14/839,038 patent/US9675600B2/en active Active
- 2015-08-28 MX MX2017002825A patent/MX361741B/es active IP Right Grant
- 2015-08-28 PL PL15838548T patent/PL3188599T3/pl unknown
- 2015-08-28 CN CN201811119404.7A patent/CN109172575A/zh active Pending
- 2015-08-28 PT PT158385484T patent/PT3188599T/pt unknown
- 2015-08-28 MD MDA20170025A patent/MD4710C1/ro active IP Right Grant
- 2015-08-28 BR BR112017003552A patent/BR112017003552A2/pt not_active Application Discontinuation
- 2015-08-28 AP AP2017009772A patent/AP2017009772A0/en unknown
- 2015-08-28 CN CN201710646685.0A patent/CN107375285A/zh active Pending
- 2015-08-28 KR KR1020187020062A patent/KR102234319B1/ko active Active
- 2015-08-28 WO PCT/US2015/047435 patent/WO2016036598A1/en not_active Ceased
- 2015-08-28 LT LT15838548T patent/LT3188599T/lt unknown
- 2015-08-28 EP EP15838548.4A patent/EP3188599B1/en active Active
- 2015-08-30 JO JOP/2015/0210A patent/JO3541B1/ar active
- 2015-09-01 TW TW104128838A patent/TWI639429B/zh active
- 2015-09-02 UY UY0001036286A patent/UY36286A/es not_active Application Discontinuation
- 2015-09-03 AR ARP150102818A patent/AR103118A1/es unknown
-
2017
- 2017-02-20 IL IL250692A patent/IL250692B/en active IP Right Grant
- 2017-03-02 CL CL2017000494A patent/CL2017000494A1/es unknown
- 2017-03-02 PH PH12017500392A patent/PH12017500392B1/en unknown
- 2017-03-03 NI NI201700024A patent/NI201700024A/es unknown
- 2017-03-03 DO DO2017000055A patent/DOP2017000055A/es unknown
- 2017-03-03 SV SV2017005400A patent/SV2017005400A/es unknown
- 2017-03-30 EC ECIEPI201719893A patent/ECSP17019893A/es unknown
- 2017-04-03 CO CONC2017/0003263A patent/CO2017003263A2/es unknown
- 2017-05-09 US US15/590,025 patent/US10278964B2/en active Active
-
2018
- 2018-06-14 JP JP2018113592A patent/JP6923486B2/ja active Active
-
2019
- 2019-02-14 US US16/275,669 patent/US10894041B2/en active Active
- 2019-12-16 CY CY20191101321T patent/CY1122746T1/el unknown
-
2020
- 2020-12-11 US US17/119,482 patent/US11723902B2/en active Active
-
2021
- 2021-02-26 JP JP2021029775A patent/JP7044918B2/ja active Active
-
2023
- 2023-06-22 US US18/212,720 patent/US20240024303A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000494A1 (es) | Tratamientos médicos a base de anamorelina. | |
| TWD196868S (zh) | 超音波治療手持件 | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MX2013004817A (es) | Enfermedad inflamatoria. | |
| BR112017023170A2 (pt) | dispositivo de banho medicinal e seu uso | |
| MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
| MX2020003049A (es) | Semaglutida en la terapia medica. | |
| TWD196867S (zh) | 超音波治療車 | |
| MX2015011671A (es) | Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| EA201071209A1 (ru) | Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови | |
| GB2554591A (en) | Clinical support system and method | |
| UA108975C2 (uk) | Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями | |
| CL2015002951A1 (es) | Silicato de zirconio microporoso y diuréticos para la reducción de potasio y el tratamiento de una enfermedad crónica del riñón y/o crónica del corazón. | |
| GT201700041A (es) | Tratamientos médicos a base de anamorelina | |
| BR112018068910A2 (pt) | sultiame para o tratamento de apneia do sono | |
| NZ740722A (en) | Oral suspension for treating eosinophilic esophagitis | |
| EA201991866A1 (ru) | Комбинированная терапия | |
| EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
| AR081669A1 (es) | Semuloparina para uso como un tratamiento antitrombotico en cirugia ortopedica con perfil beneficio-riesgo mejorado | |
| PL417551A1 (pl) | Zastosowanie insuliny do leczenia stopy cukrzycowej w formie iniekcji bezpośredniej w chorą stopę | |
| TH158984A (th) | สารประกอบที่ออกฤทธิ์ในการรักษาและวิธีการใช้ของสารประกอบดังกล่าว | |
| CN105476179A (zh) | 一种施药式保健鞋垫 | |
| UA112033U (uk) | Спосіб лікування ускладненої варикозної хвороби нижніх кінцівок |